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Abstract
Neuroinflammation (microglial activation) and subclinical nigrostriatal dysfunction have been reported in subjects at risk of 
Parkinsonism. Eight non-manifesting carriers (NMCs) of LRRK2 G2019S mutation had 11C-PK11195 and 18F-DOPA PET 
to assess microglial activation and striatal dopamine system integrity, respectively. Comparisons were made with healthy 
controls. Five LRRK2-NMCs had subclinical reductions of putaminal 18F-DOPA uptake. Three of them had significantly 
raised nigral 11C-PK11195 binding bilaterally. These findings indicate that nigrostriatal dysfunction and neuroinflammation 
occur in LRRK2-NMCs. Studies in larger cohorts with appropriate follow-up are needed to elucidate the significance of 
neuroinflammation in the premotor phase of LRRK2-PD.
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Mutations in the leucine-rich repeat kinase 2 gene (LRRK2) 
are known to cause inherited Parkinson’s disease (PD). 
LRRK2-associated PD (LRRK2-PD) presents with a low 
penetrant autosomal-dominant inheritance pattern with a 
cumulative risk of developing PD ranging from 26 to 80% 
at the age of 80 years [1, 2]. Patients with the G2019S 
mutation, the most common mutation in LRRK2-PD, are 
clinically indistinguishable from idiopathic PD and most 
cases present similar pathological findings with degenera-
tion of dopaminergic neurons in the substantia nigra and 
occurrence of Lewy-type α-synuclein pathology [3]. Study-
ing non-manifesting carriers (NMCs) of the LRRK2 G2019S 
mutation provides an opportunity to identify pathophysio-
logical processes occurring in the premotor phase of genetic 
PD. This is essential to identify biomarkers and therapeutic 
targets to halt disease progression.
Microglia, the major resident immune cells of the central 
nervous system, monitors the brain milieu in their resting 
physiologic state, but when activated by injury, they can 
express both neuroprotective and cytotoxic phenotypes. It 
is hypothesized that a pro-inflammatory phenotype, lead-
ing to neuronal dysfunction, may drive neurodegeneration 
[4]. Microglial activation has been observed in idiopathic 
PD [5], but its role in the pathophysiology of genetic PD is 
unknown. A recent study using positron emission tomogra-
phy (PET) imaging demonstrated increased microglial acti-
vation in the substantia nigra along with putaminal dopa-
minergic dysfunction in patients with idiopathic rapid eye 
movement sleep behavior disorder [6], a condition that may 
progress over time to a neurodegenerative alpha-synucle-
inopathy [7].
Morten Gersel Stokholm and Alicia Garrido contributed equally to 
the manuscript.
 * Nicola Pavese 
 npavese@cfin.au.dk
1 Department of Nuclear Medicine and PET Centre, Aarhus 
University Hospital, Noerrebrogade 44, bldg. 10G, 
8000 Aarhus C, Denmark
2 Movement Disorders Unit, Neurology Service, Hospital 
Clínic de Barcelona, Barcelona, Spain
3 Centro de Investigación Biomédica en Red Sobre 
Enfermedades Neurodegenerativas (CIBERNED), Hospital 
Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain
4 Department of Neurology, Hospital Clínic de Barcelona, 
Barcelona, Spain
5 Department of Neurology, Aarhus University Hospital, 
Aarhus C, Denmark
6 Division of Neuroscience, Newcastle University, 
Newcastle upon Tyne, England
 Journal of Neurology
1 3
The present study aimed to investigate whether raised lev-
els of microglial activation and alterations of the nigrostri-
atal dopaminergic function occur as well in LRRK2-NMCs.
Methods
Eight LRRK2-NMCs were recruited from Hospital Clínic de 
Barcelona between September 2016 and May 2018. Inclu-
sion of LRRK2-NMC was based on the absence of Parkin-
sonism and availability to perform the study. All NMC had 
a 60.5-min 11C-(R)-PK11195 PET scan (ECAT HRRT; CTI/
Siemens, Knoxville, TN, USA) to assess levels of microglial 
activation (expressing 18-kDa translocator protein) and a 
94.5-min 18F-DOPA PET scan to assess the integrity of the 
dopaminergic system. Each subject had a T1-weighted MRI 
(3 T MAGNETOM Skyra, Siemens Healthcare, Germany) 
performed for co-registration of PET images. PET find-
ings were compared with those of 29 healthy controls (11C-
PK11195 PET n = 20, 18F-DOPA PET n = 9). Control PET 
scans were acquired for two former projects using the exact 
same scanner and scan protocols [6, 8]. All participants were 
examined to exclude Parkinsonism. Assessments with the 
MDS-UPDRS part III, and Mini-Mental State Examination 
were also performed. All the assessments of this study were 
performed at the Department of Nuclear Medicine and PET 
Centre, Aarhus University Hospital.
Volumes of interest (VOI) sampled included the sub-
stantia nigra (11C-PK11195 PET only) plus putamen and 
caudate nucleus for both PET tracers. Image analysis was 
performed as previously described [6]. Briefly, parametric 
images of 11C-PK11195 binding potentials  (BPND) were 
generated using a simplified reference tissue model with an 
individual tissue non-specific input function extracted with 
a supervised cluster-analysis approach. Similarity between 
the 11C-PK11195 reference input function extracted from 
LRRK2-NMCs and controls was confirmed with a repeated 
measurement analysis (χ2 test, p > 0.05). In those VOI’s 
where 11C-PK11195 binding is lower than that of the 
selected reference tissue voxels, this model computes a nega-
tive  BPND. 18F-DOPA influx constant (Ki) images were gen-
erated using the Patlak graphical approach with the occipital 
lobe as the non-specific uptake reference region.
Group differences in 11C-PK11195  BPnd and 18F-DOPA 
Ki were interrogated with unpaired Student’s t test (p < 0.05), 
normal distribution of data was checked with normal prob-
ability plots and D’Agostino–Pearson normality test. For 
descriptive purposes, individually raised regional 11C-
PK11195 binding and reduced regional 18F-DOPA uptake 
was defined as a statistically significant deviation from the 
controls mean value (left and right side averaged) of two or 
more standard deviations (z score ≥ 2 and z score ≤ − 2). Sta-
tistical analysis and graphical presentations were performed 
in Stata IC 14.2 (StataCorp LP, TX, USA) and GraphPad 
Prism 8 (GraphPad Software, La Jolla, CA, USA).
Results
Eight LRRK2-NMCs, 7 men, with a mean UPDRS part III 
score of 2.6 (SD;1.6) and a mean age of 55.8 years (range 
39.8–73.4), were compared to 20 11C-PK11195 controls (12 
men, mean age 66.8 years, range 58–80) and 9 18F-DOPA 
controls (9 men, mean age 64.6 years, range 59.9–69.5). 
The left–right averaged putaminal 18F-DOPA uptake was 
significantly (p = 0.006) reduced by − 9.2% (range − 16.9% 
to 4.7%) in LRRK2-NMCs compared to controls, while cau-
date 18F-DOPA uptake was similar (p = 0.468). No group dif-
ferences were observed in VOI analysis with 11C-PK11195 
PET (substantia nigra p = 0.075, putamen p = 0.678, caudate 
nucleus p = 0.695).
Five out of eight LRRK2-NMCs had reduced 18F-DOPA 
uptake in putamen (z score ≤ − 2), four unilateral and one 
bilateral (Table 1; Fig. 1). Three out of eight LRRK2-NMC 
had bilaterally raised levels of 11C-PK11195 binding in the 
substantia nigra (z score ≥ 2), coincidental with unilaterally 
reduced putaminal 18F-DOPA uptake (z score ≤ − 2) in two 
and bilaterally reduced in one (Table 1; Fig. 1). One sub-
ject had unilateral raised putaminal 11C-PK11195 binding 
without ipsilateral reduced putaminal 18F-DOPA uptake 
(Table 1). 
Discussion
This PET imaging study performed in LRRK2-NMCs found 
reduced putaminal 18F-DOPA uptake in five out of eight 
LRRK2-NMCs as previously reported in subjects without 
manifest PD carrying different subtypes of LRRK2 muta-
tions [9]. Three carriers in our cohort had bilaterally raised 
substantia nigra 11C-PK11195 binding, indicating microglial 
activation, together with reductions in putaminal 18F-DOPA 
uptake (unilaterally reduced in two subjects and bilaterally 
in one). To our knowledge, this is the first report of activated 
microglia in LRRK2-NMC.
While not in all cases, a reduced putaminal 18F-DOPA 
uptake without increased ipsilateral nigral 11C-PK11195 
binding was observed (subject 4 and 5; Fig. 1), suggesting 
that in LRRK2-NMC, dysfunction of putaminal dopamin-
ergic axonal terminals may antedate microglial activation 
in nigral cell bodies, presumed to be related with neuro-
degeneration [4]. A similar pattern (normal range sub-
stantia nigra 11C-PK11195 binding and reduced ipsilateral 
putaminal 18F-DOPA uptake) has been reported previously 
in occasional subjects with prodromal PD [6] and manifest 
idiopathic PD patients [5]. The significance of microglial 
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activation in the pathophysiology of PD is yet to be estab-
lished. The findings in the current study, together with those 
found in a previous one examining prodromal PD [6] support 
the concept that similar alterations occur in the premotor 
phase in both genetic and idiopathic forms of the disease. 
Microglial cells are able to express either a neuroprotective 
or a cytotoxic phenotype [4]. Which of these is occurring in 
the examined LRRK2-NMC can only be determined with 
PET tracers binding specifically to each microglia pheno-
type; however, this kind of in vivo tracer is currently not 
available.
There are limitations to this study to be considered. 
First, the small number of cases examined may preclude 
the generalization of the results. Second, the LRRK2-NMC 
included in this study are younger than the controls which 
may account for a selection bias. Considering the age-related 
and low and penetrance of LRRK2 G20109S mutation [1, 2], 
it is possible that we have studied subjects who will never 
develop PD or at a very early phase of the disease when bio-
chemical and pathological events have not yet started [10]. 
However, the alteration of 18F-DOPA PET in five LRRK2-
NMC indicates that in most of LRRK-NMC in this cohort, 
pathological changes are already occurring. Given that age 
is the greatest risk factor for developing LRRK2-PD, we 
investigated whether PET findings were more likely to occur 
in the eldest LRRK2-NMC. We found that age did not cor-
relate with PET alterations in the studied cohort, suggest-
ing that other factors may influence 18F-DOPA dysfunction 
and microglial activation (individual data including age, not 
shown to avoid subject identification). Third, as previously 
Table 1  11C-PK11195  BPnd and 18F-DOPA Ki in controls and non-manifesting LRRK2 carriers
Values from both left and right side are averaged in the group analysis. Values are mean and standard deviation in brackets. *p < 0.05 in group 
analysis
Unilateral (○) or bilateral (●) reduced putaminal 18F-DOPA Ki value (z score ≤ − 2) and/or raised substantia nigra 11C-PK11195  BPND (z 
score ≥ 2) in individual carriers
NMCs non-manifesting carriers, UPDRS-III Unified Parkinson’s Disease Rating Scale—part three, MMSE Mini-Mental State Examination
11C-PK11195  BPnd 18F-DOPA Ki
Controls (n = 20) LRRK2-NMCs (n = 8) Controls (n = 9) LRRK2-NMCs (n = 8)
Group analysis
 Substantia nigra − 0.006 (0.09) 0.08 (0.16) – –
 Putamen 0.08 (0.11) 0.06 (0.13) 0.0131 (0.00069) 0.0120* (0.00087)
 Caudate − 0.15 (0.12) − 0.17 (0.13) 0.0113 (0.00085) 0.0120 (0.0017)
Reduced putamen
18F-DOPA Ki
Raised substantia nigra
11C-PK11195  BPnd
Raised putamen
11C-PK11195  BPnd
UPDRS-III MMSE
Individual analysis
 Carrier 1 0 28
 Carrier 2 5 30
 Carrier 3 ○ ● 4 30
 Carrier 4 ○ 3 30
 Carrier 5 ○ 2 29
 Carrier 6 3 30
 Carrier 7 ● ● 3 29
 Carrier 8 ○ ● ○ 1 26
Fig. 1  18F-DOPA uptake in putamen and ipsilateral 11C-PK11195 
binding in substantia nigra in non-manifesting LRRK2 G2019S car-
riers. Values from left and right side in eight non-manifesting LRRK2 
G2019S carriers are depicted. ⨂ indicates significantly reduced 
18F-DOPA Ki values, which are two or more standard deviations 
below the average mean of controls (z score ≤ − 2). Red colour indi-
cates significantly raised 11C-PK11195  BPND two or more standard 
deviations above the average mean of controls (z score ≥ 2). Obser-
vations from each individual carrier are marked with numbers from 
one to eight, which corresponds to their number in Table 1, individual 
analysis
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reported in animal models [11], levels of microglial activa-
tion in PD may be influenced by the presence of pathological 
α-synuclein inclusions. In LRRK2 G2019S PD, a pleiotropic 
neuropathology has been reported, including subjects with-
out Lewy-type α-synuclein pathology [3, 12]. This patho-
logical variability may possibly influence the heterogeneity 
of the results. Finally, 11C-PK11195 may not only bind to the 
18-kDa translocator protein located on mitochondria inside 
the activated microglial cells but also on astrocytes; how-
ever, observations show that this only accounts for minor 
degree of 11C-PK11195 signal [13].
This is the first study performed in LRRK2-NMCs show-
ing dopamine dysfunction in five out of eight subjects and 
concomitant nigral microglial activation in three of them. 
These results suggest that PET imaging with 18F-DOPA 
and 11C-PK11195 could help identify NMCs with ongoing 
nigrostriatal pathology and show that at least in some cases, 
neuroinflammation could play a role in the pathophysiol-
ogy of early phases of LRRK2-PD. The contribution of the 
observed in vivo microglial response and its clinical rel-
evance at individual level still needs to be elucidated. Pro-
spective studies using similar PET tracers in a larger study 
population with appropriate clinical follow-up may clarify 
these issues.
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